Home » SURFACE LOGIX BEGINS TRIAL FOR GASTROINTESTINAL-SPECIFIC MTP INHIBITOR
SURFACE LOGIX BEGINS TRIAL FOR GASTROINTESTINAL-SPECIFIC MTP INHIBITOR
Surface Logix today announced the commencement of a Phase I clinical trial for SLx-4090, a novel, Microsomal Triglyceride Transfer Protein (MTP) inhibitor targeting dyslipidemia.
The trial is a single-center, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of a range of single orally administered doses of SLx-4090 in healthy male subjects.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May